Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

Combination Therapy Induces High Response Among Relapsed/Refractory Follicular Lymphoma
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma
Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.The Cochrane Review used n...
Source: Cochrane News and Events - November 26, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

Lenalidomide Slows Progression of Smoldering Multiple Myeloma Lenalidomide Slows Progression of Smoldering Multiple Myeloma
Early treatment with lenalidomide significantly delays the progression of smoldering multiple myeloma to symptomatic disease, according to the results of a randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Lenalidomide Delays Progression in Smoldering Multiple Myeloma
THURSDAY, Nov. 7, 2019 -- Lenalidomide significantly delays progression to symptomatic multiple myeloma in patients with smoldering multiple myeloma, according to a study published online Oct. 25 in the Journal of Clinical Oncology. Sagar Lonial,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2019 Category: Pharmaceuticals Source Type: news

Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone. (Source: CancerNetwork)
Source: CancerNetwork - October 29, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Lenalidomide may delay onset of myeloma-related bone, organ damage
ROCHESTER Minn. -- The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 26, 2019 Category: Research Source Type: news

lenalidomide (Revlimid)
Title: lenalidomide (Revlimid)Category: MedicationsCreated: 3/25/2015 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news

Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with  relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

GALEN Study Examines Lenalidomide, Obinutuzumab Combo in Follicular Lymphoma
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - July 16, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

FDA Approves Daratumumab Combination For Multiple Myeloma
The FDA approved daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX ® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 27, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces FDA Approval of Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news

Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2019 Category: International Medicine & Public Health Source Type: news

Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in  relapsed/refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in  relapsed/refractory large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Daratumumab Triplet for First-Line Myeloma, but Questions Remain Daratumumab Triplet for First-Line Myeloma, but Questions Remain
The daratumumab, lenalidomide, and dexamethasone triplet is a new frontline option for patients with multiple myeloma who are not candidates for transplant, but how practice-changing are the data?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 29, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Daratumumab Cuts Risk for Progression in Multiple Myeloma
WEDNESDAY, May 29, 2019 -- For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 29, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Combo for Indolent Non-Hodgkin Lymphomas FDA Approves Combo for Indolent Non-Hodgkin Lymphomas
Lenalidomide may now be used in combination with rituximab for previously treated follicular lymphoma and previously treated marginal zone lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves lenalidomide for follicular and marginal zone lymphoma
Hematology/Oncology News Burs (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 29, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
SUMMIT, N.J.--(BUSINESS WIRE) May 28, 2019 -- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 28, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomide Delays Onset of Multiple Myeloma Lenalidomide Delays Onset of Multiple Myeloma
In patients with both high-risk and intermediate smoldering myeloma, treatment with single-agent lenalidomide significantly delayed progression to full-blown disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Multiple myeloma: DNA rearrangement may predict poor outcomes
(Emory Health Sciences) In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2019 Category: Cancer & Oncology Source Type: news

Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame
President and CEO of  Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers. Internationally recognized for his contributions in the development of more effective treatment strategies for myelodysplasti c syndrome and acute myeloid leukemia, List's work led to the development of lenalidomide, which received approval from the U.S. Food and Drug Administration. The treatment transformed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Kelsey Sunderland Source Type: news

Big Jump in PFS With Combo for Indolent NHL
(MedPage Today) -- Lenalidomide-rituximab more than doubles PFS in relapsed/refractory disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 26, 2019 Category: Hematology Source Type: news

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Drug Combo Granted Priority Review for Untreated Follicular Lymphoma
The FDA has granted Priority Review to Celgene ’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide Maintenance vs Observation For Newly Diagnosed Myeloma
Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

MRD Status a Superior Predictor of PFS in Multiple Myeloma?
The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Addressing uncertainty in cost-effectiveness case for lenalidomide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomide cost effective in newly diagnosed multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

ASH Poster Rounds: Adding BTK Inhibitor Safe in First-Line MCL
(MedPage Today) -- Plus: Lenalidomide upfront in PTCL; skipping RT in primary mediastinal B-cell lymphoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2018 Category: Hematology Source Type: news

Daratumumab Plus Len/Dex: New Standard of Care in Myeloma? Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
Adding daratumumab to lenalidomide and dexamethasone increased progression-free survival in transplant-ineligible patients newly diagnosed with myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Early Intervention With New Drug Combo Beneficial in Myeloma?
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
WEDNESDAY, Nov. 7, 2018 -- For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2018 Category: Pharmaceuticals Source Type: news

FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma
(MedPage Today) -- Agent doubled overall response rate, progression-free survival (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 7, 2018 Category: American Health Source Type: news

Rituximab & #43; Lenalidomide Effective in Follicular Lymphoma
TUESDAY, Sept. 11, 2018 -- Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 11, 2018 Category: Pharmaceuticals Source Type: news

Obinutuzumab/Lenalidomide Combo Safe, Effective in Advanced Follicular Lymphoma
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide Consolidation Benefits CLL Patients Post Chemoimmunotherapy
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - August 2, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Does Frontline R2CHOP Reduce CNS Relapse Risk in DLBCL?
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide/Rituximab Combo Effective in Advanced FL
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma
A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
Leah LawrenceJun 3, 2018OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news